Could a tiny dose of radiation reboot cancer immunotherapy?
NCT ID NCT07164690
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their original immunotherapy. The study will track how long the cancer stays controlled and whether the combination is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiation therapy
What this could lead to
If successful, this approach could help restore the effectiveness of immunotherapy in patients whose esophageal cancer has stopped responding to standard treatment.
What could go wrong
This is a small, early-phase trial with only 32 participants and no comparison group. The benefit may be modest, and there are risks like fistula or bleeding from radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••